ПРИОБРЕТЕННАЯ РЕЗИСТЕНТНОСТЬ К ИНГИБИТОРАМ ТИРОЗИНКИНАЗЫ EGFR: ПУТИ ПРЕОДОЛЕНИЯ

ПРИОБРЕТЕННАЯ РЕЗИСТЕНТНОСТЬ К ИНГИБИТОРАМ ТИРОЗИНКИНАЗЫ EGFR: ПУТИ ПРЕОДОЛЕНИЯ

Advances in the treatment of disseminated patients with non-small cell lung cancer are directly linked to targeted therapy. Patients with activating mutations in the gene for the receptor of epidermal growth factor (EGFR) in appointing them in the first line EGFR tyrosine kinase inhibitors (EGFR TK...

Full description

Bibliographic Details
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2017-11-01
Series:	Медицинский совет
Subjects:	non-small cell lung cancer egfr tyrosine kinase inhibitors of egfr resistance osimertinib
Online Access:	https://www.med-sovet.pro/jour/article/view/2164

Similar Items

Osimertinib for the first-line treatment of EGFR-positive non-small cell lung cancer
by: Elena V Reutova, et al.
Published: (2019-09-01)

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer
by: Tejas Patil, et al.
Published: (2020-04-01)

Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
by: YanRu Qin, et al.
Published: (2020-08-01)

Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
by: Peng D, et al.
Published: (2021-02-01)

New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors
by: K K Laktionov, et al.
Published: (2018-06-01)

Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation—Positive Lung Cancer Cells
by: Paulina Skupin-Mrugalska, et al.
Published: (2020-09-01)

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy
by: K. A. Sarantseva, et al.
Published: (2020-12-01)

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature
by: Izumi Sato, et al.
Published: (2020-08-01)

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
by: Donatella Romaniello, et al.
Published: (2020-08-01)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
by: Yu Saida, et al.
Published: (2019-11-01)

EGFR targeted therapy in lung cancer; an evolving story
by: C. Bartholomew, et al.
Published: (2017-01-01)

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
by: Diego Enrico, MD, et al.
Published: (2020-06-01)

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
by: Yu D, et al.
Published: (2021-02-01)

Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation
by: Alexandre Schaller, et al.
Published: (2014-11-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)

Research Progress on Resistance Mechanisms and Overcoming Strategies to Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer
by: HE Jingyi, et al.
Published: (2019-10-01)

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
by: Wang X, et al.
Published: (2016-09-01)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
by: Xie Y, et al.
Published: (2021-10-01)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
by: Hongjing Zang, et al.
Published: (2020-04-01)

The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations
by: Jiarong Tan, et al.
Published: (2021-08-01)

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
by: Yuko Oya, et al.
Published: (2021-01-01)

EGFR Mutation as a Predictive Factor to Treatment Response of TKI (Tyrosine Kinase Inhibitor) in Non-Small Cell Lung Cancer Stage 4: A Case Report
by: Wulyo Rajabto, et al.
Published: (2021-03-01)

Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study
by: Igawa S, et al.
Published: (2019-05-01)

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
by: Wolfgang Schuette, et al.
Published: (2018-02-01)

Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population
by: Noorwati SUTANDYO, et al.
Published: (2019-09-01)

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
by: Vito Longo, et al.
Published: (2021-07-01)

Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
by: Rintu Thomas, et al.
Published: (2019-05-01)

Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents
by: Rania S.M. Ismail, et al.
Published: (2016-06-01)

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation
by: Tadashi Nishimura, et al.
Published: (2021-04-01)

A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
by: Chul Kim, et al.
Published: (2021-09-01)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
by: Akiko Takahashi, et al.
Published: (2018-10-01)

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib∗
by: Andrew J. Piper-Vallillo, MD, et al.
Published: (2019-12-01)

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report
by: Eric Dansin, et al.
Published: (2015-03-01)

Rational approach to the treatment of EGFR-positive lung cancer
by: E. V. Reutova, et al.
Published: (2019-12-01)

The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with Т790М mutation to anti-EGFR drugs in non-small cell lung cancer
by: E V Karabina, et al.
Published: (2018-09-01)

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
by: Nobuaki Kobayashi, et al.
Published: (2020-08-01)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
by: K. K. Laktionov, et al.
Published: (2019-06-01)

Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer
by: Di Liu, et al.
Published: (2019-09-01)

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
by: Marialucia Iacovino, et al.
Published: (2020-12-01)

Cannot write session to /tmp/vufind_sessions/sess_udmu0tv5prf70avh8s3v27st69